Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Trial Profile

A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samotolisib (Primary) ; Abemaciclib; Cisplatin; Fulvestrant; Letrozole; Midazolam; Pemetrexed
  • Indications Advanced breast cancer; B-cell lymphoma; Cancer; Lymphoma; Malignant-mesothelioma; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 07 Apr 2022 Status changed from active, no longer recruiting to completed.
  • 05 Jan 2022 Planned End Date changed from 1 Oct 2021 to 31 Jan 2022.
  • 05 Aug 2021 Planned End Date changed from 1 Mar 2021 to 1 Oct 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top